16 Nov 2021
Research presented at the recent Society for Endocrinology annual conference in Edinburgh, suggests that an AstraZeneca drug that inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 may improve wound healing in type 2 diabetes patients.